Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 …

Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 …
Filed under: cocain abuse
8, 2012 (GLOBE NEWSWIRE) — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced top-line results from its U.S. Phase II(b) clinical trial evaluating the use of CPP-109 (vigabatrin) to treat cocaine addiction. The data from the trial … Read more on NASDAQ